- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT05643534
Estudio para evaluar la seguridad y eficacia de Tenapanor para el tratamiento del SII-E
Estudio de fase 3, aleatorizado, doble ciego, controlado con placebo, de 12 semanas de duración para evaluar la seguridad y la eficacia de tenapanor para el tratamiento del síndrome del intestino irritable con estreñimiento (IBS-C) en pacientes pediátricos de 12 a menos de 18 años
This is a randomized, double-blind, placebo-controlled study to assess the efficacy, safety and tolerability of tenapanor (25 mg and 50 mg) in pediatric patients (≥12 and <18 years old) with IBS-C when administered twice daily (BID) for 12 consecutive weeks.
Descripción general del estudio
Estado
Intervención / Tratamiento
Descripción detallada
This study consists of 2-week screening period followed by 12 week randomized treatment period (RTP) and a 2-week treatment-free Follow-Up period (only for patients who will not enter the 40-week Long Term Safety Extension Study [TEN-01-306]). At the beginning of the 2-week Screening period, patients who provide written assent will be fully assessed for eligibility into the study and will be asked to self-report daily information about the status of their IBS symptoms via an electronic diary (eDiary) device. Patient compliance with the eDiary will be monitored actively by the site staff and will be reviewed to determine eligibility at the end of screening. Eligible patients will be randomized to receive one of the study medications: tenapanor 25 mg BID, tenapanor 50 mg BID, or placebo.
During the 12-week double-blind RTP, patients will continue recording daily assessments via the eDiary system as instructed and compliance with eDiary entries will be monitored on an ongoing basis. Patients will return for study visit every two or four weeks (Visits 3-6) and will undergo safety assessments at these visits.
Patients who do not enter the 40-week Long Term Safety Extension Study [TEN-01-306] including those who complete the RTP but do not enter study TEN-01-306 and those who prematurely discontinue from the RTP, a Follow-Up Visit will be scheduled approximately 2 weeks after the completion of the RTP (Visit 6) or the Early Termination Visit at which safety assessments will be performed
Tipo de estudio
Inscripción (Actual)
Fase
- Fase 3
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
Alabama
-
Foley, Alabama, Estados Unidos, 36535
- G & L Research, LLC
-
-
Arizona
-
Tucson, Arizona, Estados Unidos, 85745
- Eclipse Clinical Research
-
-
Arkansas
-
Little Rock, Arkansas, Estados Unidos, 72205
- Applied Research Center of Arkansas
-
-
California
-
Anaheim, California, Estados Unidos, 92805
- Advanced Research Center, Inc.
-
-
Connecticut
-
Hartford, Connecticut, Estados Unidos, 06106
- Connecticut Children's Medical Center
-
-
Florida
-
Doral, Florida, Estados Unidos, 33166
- Prohealth Research Center
-
Kissimmee, Florida, Estados Unidos, 34741
- I.H.S. Health, LLC
-
Miami, Florida, Estados Unidos, 33165
- Valencia Medical and Research Center
-
Miami, Florida, Estados Unidos, 33155
- Waterway Research & Associates Corp
-
Orlando, Florida, Estados Unidos, 32806
- Orlando Health, Inc.- APH Center for Digestive Health and Nutrition
-
South Miami, Florida, Estados Unidos, 33143
- Florida Pharmaceutical Research and Associates, Inc.
-
-
Georgia
-
Stockbridge, Georgia, Estados Unidos, 30281
- Clinical Research Institute
-
-
Illinois
-
Peoria, Illinois, Estados Unidos, 61637
- OSF Saint Francis Medical Center
-
-
Indiana
-
Indianapolis, Indiana, Estados Unidos, 46202
- Riley Children's Health IUH
-
-
Maine
-
Portland, Maine, Estados Unidos, 04102
- Maine Health
-
-
Massachusetts
-
Boston, Massachusetts, Estados Unidos, 02115
- Boston Children's Hospital
-
-
Minnesota
-
Mankato, Minnesota, Estados Unidos, 56001
- Mankato Clinic/ Javara Research Ltd
-
-
Nebraska
-
Boys Town, Nebraska, Estados Unidos, 68010
- Boys Town National Research Hospital
-
-
New Jersey
-
Irvington, New Jersey, Estados Unidos, 07111
- Med Clinical Research Partners, LLC
-
-
New Mexico
-
Albuquerque, New Mexico, Estados Unidos, 87131
- University of New Mexico Health Sciences Center
-
-
New York
-
Brooklyn, New York, Estados Unidos, 11203
- SUNY Downstate Medical Center
-
Rochester, New York, Estados Unidos, 14642
- University of Rochester
-
The Bronx, New York, Estados Unidos, 10467
- Advantage Clinical Trials
-
-
North Carolina
-
Charlotte, North Carolina, Estados Unidos, 28203
- Atrium Health
-
Durham, North Carolina, Estados Unidos, 27705
- Duke University School of Medicine
-
Wilmington, North Carolina, Estados Unidos, 28401
- Wilmington Health
-
-
Pennsylvania
-
Scottdale, Pennsylvania, Estados Unidos, 15683
- Frontier Clinical Research, LLC
-
Smithfield, Pennsylvania, Estados Unidos, 15478
- Frontier Clinical Research, LLC
-
-
South Carolina
-
Greenville, South Carolina, Estados Unidos, 29615
- Prisma Health Children's Hospital
-
-
Texas
-
Abilene, Texas, Estados Unidos, 79606
- Advance Clinical Trial PLLC
-
El Paso, Texas, Estados Unidos, 79902
- Maspons Pediatric Gastro
-
El Paso, Texas, Estados Unidos, 79902
- Proactive El Paso, LLC
-
Harlingen, Texas, Estados Unidos, 78550
- Texas Digestive Specialists
-
Plano, Texas, Estados Unidos, 75093
- AIM Trials, LLC
-
San Antonio, Texas, Estados Unidos, 78215
- Sun Research Institute
-
Sugar Land, Texas, Estados Unidos, 77479
- Pioneer Research Solutions Inc
-
Waxahachie, Texas, Estados Unidos, 75165
- ClinPoint Trials
-
-
West Virginia
-
Huntington, West Virginia, Estados Unidos, 25701
- University Physicians and Surgeons, Inc.
-
Kingwood, West Virginia, Estados Unidos, 26537
- Frontier Clinical Research
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- ≥12 and <18 years old
- Patient weighs ≥18 kg at the time the patient provides written assent
- Females of child-bearing potential must have negative pregnancy test at Visit 1 (serum) and Visit 2 (urine) and confirm the use of appropriate contraception (including abstinence).
- Patient meets the Rome IV criteria for child/adolescent diagnosis of IBS-C
- Patient is willing to discontinue any laxatives used in favor of the protocol-permitted rescue medicine (which will only be allowed after 72 hours with no bowel movement)
- Patient meets the entry criteria assessed during the 2-week Screening period.
- Ability of both the patient and parent/guardian/LAR to communicate with the Investigator and to comply with the requirements of the entire study, including an understanding of the assessments in the eDiary and how to use the eDiary device
- Patient must provide written assent and the parent/guardian/LAR must provide written informed consent before the initiation of any study-specific procedures
Exclusion Criteria:
-
Functional diarrhea as defined by Rome IV child/adolescent criteria
-
IBS with diarrhea (IBS-D), mixed IBS (IBS-M), or unsubtyped IBS as defined by Rome IV child/adolescent criteria
-
History of non-retentive fecal incontinence.
-
Required manual disimpaction any time prior to randomization (after consent);
-
Has both unexplained and clinically significant alarm symptoms (lower gastrointestinal [GI] bleeding [rectal bleeding or heme-positive stool], iron-deficiency anemia, or any unexplained anemia, or weight loss) and systemic signs of infection or colitis, or any neoplastic process
-
Patient has any of the following conditions:
- Celiac disease, or positive serological test for celiac disease
- Cystic fibrosis
- Hypothyroidism that is untreated or treated with thyroid hormone
- Down's syndrome or any other chromosomal disorder
- Active anal fissure
- Anatomic malformations (eg, imperforate anus)
- Intestinal nerve or muscle disorders (eg, Hirschprung disease)
- Neuropathic conditions (eg, spinal cord abnormalities)
- Lead toxicity, hypercalcemia
- Neurodevelopmental disabilities producing a cognitive delay that precludes comprehension and completion of the daily eDiary (Electronic handheld device)
- Inflammatory bowel disease
- Childhood functional abdominal pain syndrome
- Childhood functional abdominal pain;
- Poorly treated or poorly controlled psychiatric disorders that might influence his or her ability to participate in the study;
- Lactose intolerance that is associated with abdominal pain or discomfort
- History of cancer other than treated basal cell carcinoma of the skin; (Note: Patients with a history of cancer are allowed provided that the malignancy has been in a complete remission for at least 5 years before the Randomization Visit.)
- History of diabetic neuropathy.
-
Use of medications that are known to affect stool consistency (Prohibited Medications), including fiber supplements, anti-diarrheals, cathartics, antacids, opiates, prokinetic drugs, laxatives, enemas, antibiotics during the Screening period; unless specified as rescue medication, and used accordingly as directed by the Investigator.
-
Patient has had surgery that meets any of the following criteria:
- Bariatric surgery for treatment of obesity, or surgery to remove a segment of the GI tract at any time before the Screening Visit;
- Surgery of the abdomen, pelvis, or retroperitoneal structures during the 6 months before the Screening Visit;
- An appendectomy or cholecystectomy during the 60 days before the Screening Visit;
- Other major surgery during the 30 days before the Screening Visit
-
History of alcohol or substance abuse
-
Participation in other clinical trials within 1 month prior to Screening
-
Patient and/or parent/guardian/LAR is involved in the conduct and/or administration of this trial as an investigator, sub-investigator, trial coordinator, or other staff member, or the patient is a first-degree family member, significant other, or relative residing with one of the above persons involved in the trial
-
If, in the opinion of the Investigator, the patient is unable or unwilling to fulfill the requirements of the protocol or has a condition, which would render the results uninterpretable
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Doble
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: Tenpanor 50 mg BID
Patients will be randomized to receive 50 mg tenapanor twice daily |
Participants will receive tenapanor 50 mg BID (total of 100 mg daily) |
|
Experimental: Tenpanor 25 mg BID
Patients will be randomized to receive 25 mg tenapanor twice daily |
Participants will receive tenapanor 25 mg BID (total of 50 mg daily) |
|
Comparador de placebos: Placebo Comparator
Patients will be randomized to receive matching placebo twice daily |
Participants will be randomized to receive matching placebo |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
6/12-week APS (abdominal pain and SBM) +2 response
Periodo de tiempo: 12 weeks
|
6/12-week APS (abdominal pain and SBM (spontaneous bowel movement)) +2 response, defined as achieving the weekly APS +2 response criteria (i.e., achieving both weekly SBM +2 response and weekly abdominal pain response during the same week) for ≥6 out of the 12 weeks of the RTP.
|
12 weeks
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
6/12-week SBM +2 response
Periodo de tiempo: 12 weeks
|
6/12-week SBM +2 response: defined as achieving the weekly SBM +2 response for ≥6 out of the 12 weeks of the RTP |
12 weeks
|
|
6/12-week abdominal pain response
Periodo de tiempo: 12 weeks
|
6/12-week abdominal pain response: defined as achieving the weekly abdominal pain response for ≥6 out of the 12 weeks of the RTP |
12 weeks
|
|
Change from baseline in average weekly SBM frequency
Periodo de tiempo: 12 weeks
|
Change from baseline in average weekly SBM frequency |
12 weeks
|
|
Change from baseline in average weekly stool consistency score
Periodo de tiempo: 12 weeks
|
Change from baseline in average weekly stool consistency score |
12 weeks
|
|
Change from baseline in average weekly abdominal pain score
Periodo de tiempo: 12 weeks
|
Change from baseline in average weekly abdominal pain score |
12 weeks
|
|
Overall use of rescue medication
Periodo de tiempo: 12 weeks
|
Overall use of rescue medication |
12 weeks
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Director de estudio: Jocelyn Tabora, Ardelyx
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- TEN-01-304
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .